Ongoing Class II recall of ready-to-use intravenous amiodarone

The FDA sweep carries an ongoing Class II recall of a premixed amiodarone hydrochloride presentation, 360 mg in 200 mL, supplied in a single-dose flexible container. The stated reason is deviation from current good manufacturing practice. Class II means use may cause temporary or medically reversible harm, with serious harm unlikely.

This is a manufacturing and supply matter, not a safety finding about amiodarone. The clinical consequence is availability: premixed amiodarone exists precisely because compounding it at the bedside during a tachyarrhythmia is error-prone, and a resuscitation trolley stocked on the assumption the premix is there behaves differently when it is not.

Check stock against the recall notice, and if the premix is unavailable, make sure whoever is drawing up amiodarone in an emergency has the dilution written down rather than remembered.

• Audit resuscitation trolley and critical care stock against the current recall notice.
• If premixed product is withdrawn, post the dilution and infusion rate at the point of use.
• Confirm the substitute presentation is compatible with the giving sets in stock.
• Tell pharmacy before the shelf is empty rather than after.
• Nothing here changes the indications for or the dosing of amiodarone.

Why it matters

Losing a ready-to-use presentation moves a calculation back to the bedside in the middle of an arrhythmia, which is where it used to go wrong.

Don't overread it

A Class II recall for manufacturing deviations is an administrative and supply action, not evidence of harm from the drug.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.